buy upgrad buy comfort
valuat base eylea dupix
messag reason side line uncertainti regard
eylea competitor develop dupix sale trend address
satisfact eylea competitor may weaker imagin dupix launch
trajectori sound like get better consensu dupix
regn valuat support eylea dupix franchis
essenti trade near zero pipelin valu pipelin meaning
driver view therefor upgrad buy
neutral target
dupix growth base busi addit
label expans profil may defend
lead drug approv competitor approach howev underli
mechan ensur clinic commerci moat around dupilumab view
could either blunt impact competitor reach market ensur
dupilumab remain best treatment option certain set patient key advantag
dupilumab abil address multipl condit atop dermat asthma nasal
polyposi eosinophil esophag other often present togeth
ensur dupilumab best suit drug treat dupilumab approv
aderm asthma report posit phase data patient nasal polyp
dupix aderm sale miss consensu beat total
prescript grew base weekli im data correspond
sale increas us date period
impli sale consensu direct-
to-consum dtc campaign also begun persist report
first prescript refil combin data point give us
confid dupix continu grow atop dermat current valu
dupilumab per share per share us per share outsid us
potenti competitor mani includ late stage base clinicaltri gov
success dupix aderm like encourag competitor enter field
sinc remain larg competit white space number pivot readout
expect balanc risk-benefit profil dupilumab plu abil work
across multipl atop disord could provid barrier entri competitor unless
markedli differ term valu deliv patient
continu follow page
page analyst certif import disclosur
exhibit dupix competit ad
exhibit dupix competit asthma
though market competit includ biolog drug alreadi market dupix differenti characterist
includ option self-administr activ co-morbid condit label allow usag oral corticosteroid depend
page analyst certif import disclosur
